Tesamorelin
Tesamorelin scored 6.0 / 10 (👍 Worth trying) on the BioHarmony scale as a Growth hormone peptide (FDA-approved stabilized GHRH analogue).
Tesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for hepatic fat reduction, but cost, daily injections, reversibility, cancer contraindications, and anti-doping prohibition keep the score at 6.0–6.5/10.
What is Tesamorelin?
Tesamorelin is a prescription peptide that mimics growth hormone-releasing hormone and stimulates the pituitary GHRH receptor. Instead of injecting growth hormone directly, tesamorelin amplifies endogenous pulsatile GH release and raises downstream IGF-1. The practical result is a selective lipolytic signal that reduces visceral adipose tissue in the FDA-approved HIV lipodystrophy population while largely preserving subcutaneous fat.
The clearest clinical use is excess abdominal fat in adults with HIV-associated lipodystrophy. Falutz 2007 is the landmark Phase 3 trial behind approval, and the current FDA 2025 label keeps the indication narrow: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, not weight loss. The DHHS/NIH HIV guidelines also describe tesamorelin as the only US FDA-approved therapy for excessive abdominal fat in people with HIV, while warning that effects reverse after stopping.
Off-label interest comes from three adjacent signals. First, tesamorelin improves visceral-fat and metabolic markers in responders, as summarized by Stanley 2012. Second, HIV-associated fatty-liver data from Stanley 2019 and hepatic transcriptomic work from Fourman 2020 suggest a liver-fat and fibrosis-pathway role. Third, cognition data from Baker 2012 created interest in GH-axis restoration for older adults and MCI, though Ellis 2025 tempers the neurocognitive enthusiasm in HIV. A 2026 meta-analysis by Badran 2026 reinforces the body-composition and hepatic-fat direction but does not remove the core limitation: tesamorelin is expensive, injectable, reversible, contraindicated in key groups, and WADA-prohibited in sport.
Terminology
For the regulatory baseline, see the FDA prescribing label.
- GHRH: Growth hormone-releasing hormone. A hypothalamic peptide that tells the pituitary to release growth hormone in pulses.
- GHRH analog: A synthetic peptide that mimics GHRH. Tesamorelin is stabilized so it lasts longer than native GHRH.
- GH: Growth hormone. A pituitary hormone involved in growth, lipolysis, repair, and metabolism.
- IGF-1: Insulin-like growth factor 1. A downstream hormone used as the main blood marker of GH-axis activity.
- GHRHR: Growth hormone-releasing hormone receptor. The pituitary receptor tesamorelin stimulates.
- VAT: Visceral adipose tissue. Deep abdominal fat around organs, strongly tied to cardiometabolic risk.
- SAT: Subcutaneous adipose tissue. Fat under the skin, generally preserved during tesamorelin therapy.
- Lipodystrophy: Abnormal fat distribution. HIV-associated lipodystrophy often combines central fat gain with peripheral fat changes.
- NAFLD / MASLD: Fatty liver disease not primarily driven by alcohol. MASLD is the newer metabolic-dysfunction terminology.
- MASH: Metabolic dysfunction-associated steatohepatitis, the newer term replacing NASH.
- HbA1c: A roughly 3-month blood-glucose exposure marker. Tesamorelin can modestly worsen glucose markers in susceptible users.
- IGF-1 monitoring: Periodic blood testing to keep IGF-1 within the age-adjusted reference range.
- 503A / 503B compounding: US pharmacy compounding pathways. Tesamorelin has an approved commercial product, so routine low-cost compounding is not the same as approved Egrifta SV.
- DPP-IV: Dipeptidyl peptidase-4, an enzyme that rapidly degrades native GHRH. Tesamorelin is modified to resist this breakdown.
- WADA: World Anti-Doping Agency. WADA prohibits tesamorelin at all times because it is a growth hormone-releasing factor.
How do you take Tesamorelin?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection (brand Egrifta SV) | Lyophilized powder reconstituted with sterile water, single-use vial | 2 mg daily FDA-approved protocol for HIV-associated lipodystrophy. Abdominal injection preferred with site rotation. | 1 mg to 2 mg daily Off-label VAT, NAFLD, and metabolic-health use generally follows label timing but often starts below label dose. |
| Subcutaneous injection (non-approved compounded or research supply) | Lyophilized powder reconstituted with bacteriostatic water, multi-use vial | Not applicable in the US because the approved commercial product limits routine compounding pathways FDA-approved tesamorelin exists commercially. Off-label clinic or research-peptide supply is outside the approval package. | 1 mg to 4 mg daily Used by some biohackers for cost reasons. Quality varies by supplier and independent sterility/endotoxin verification is often absent. |
Protocols
HIV-associated lipodystrophy (FDA-approved) Clinical
- Dose
- 2 mg subcutaneous daily in the evening
- Frequency
- Daily
- Duration
- Continuous; pivotal trials evaluated 26 weeks with safety-extension data through 52 weeks
[Falutz 2007](https://pubmed.ncbi.nlm.nih.gov/18057338/) supports VAT reduction over 26 weeks; [Falutz 2010](https://pubmed.ncbi.nlm.nih.gov/20101189/) supports the safety-extension pattern. Benefits regress after stopping.
HIV-associated NAFLD / MASLD specialist protocol Clinical
- Dose
- 2 mg subcutaneous daily
- Frequency
- Daily
- Duration
- 12 months in the main HIV-NAFLD randomized trial
[Stanley 2019](https://pubmed.ncbi.nlm.nih.gov/31611038/) tested HIV-associated NAFLD over 12 months. Use requires liver imaging, glucose monitoring, and specialist oversight.
Cognitive aging / MCI research protocol Clinical
- Dose
- 1 mg subcutaneous daily before bedtime
- Frequency
- Daily
- Duration
- 20 weeks
[Baker 2012](https://pubmed.ncbi.nlm.nih.gov/22869065/) used a GHRH analog protocol in older adults and MCI. Cognitive use remains research-grade, not an FDA-approved indication.
Off-label VAT / longevity-oriented biohacker protocol Mixed
- Dose
- 1 mg subcutaneous nightly
- Frequency
- Daily or 5 days on / 2 days off
- Duration
- 8 to 16 weeks for short cycles; 6 to 12 months for imaging-confirmed VAT or liver-fat goals
Lower-dose use is common but not equivalent to the approval evidence. Monitor IGF-1, fasting glucose, HbA1c, edema, arthralgia, and injection reactions.
Stacked GHRH + GHRP protocol Anecdotal
- Dose
- Tesamorelin 1 mg plus ipamorelin 200 to 300 mcg before bed
- Frequency
- Daily or cyclic
- Duration
- 8 to 16 weeks
Mechanistically targets GHRH and ghrelin/GHRP pathways. No RCTs validate stacked dosing. Stacking with CJC-1295 is usually redundant because both stimulate the GHRH receptor.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of Tesamorelin?
Upside contribution: 2.84
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | Strong | 1.075 | |
| Breadth | 15% | Strong | 0.585 | |
| Evidence | 25% | Exceptional | 1.125 | |
| Speed | 10% | Moderate | 0.260 | |
| Durability | 10% | Limited | 0.160 | |
| Bioindividuality | 15% | Strong | 0.630 | |
| Total | 3.835 | |||
| Baseline offset (constant) | −1.000 | |||
| Effective upside contribution | 2.835 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Upside Rationale
Tesamorelin has its strongest upside when the reader wants body composition, hormonal, and metabolic-health improvement and can use it in the studied context. Badran et al. 2026 gives the score a real evidence anchor, while Russo et al. 2024 helps define where the effect is narrower or broader. The practical value is a specific endocrine lever that matters most when HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight already point the same way. The upside is strongest when mechanism, population, and outcome line up instead of borrowing confidence from neighboring claims. In a stack, it belongs only after the higher-use basics are already stable.
Efficacy (Strong): Tesamorelin sits in the moderate-to-large SM-032 band on hard imaging endpoints rather than surrogates. Falutz 2007, a Phase 3 randomized trial, showed roughly 15 percent visceral adipose tissue reduction against placebo at 26 weeks with subcutaneous fat preserved, Stanley 2019 cut fibrosis progression to 10.5 percent against 37.5 percent on placebo in HIV-associated NAFLD, and Badran 2026 pooled five RCTs confirming visceral, trunk, hepatic and waist reductions with increased lean mass. Tesamorelin stops short of the transformative band because the effect is conditional on a high-visceral-fat or HIV-defined phenotype, per SM-025.
Breadth of benefits (Strong): Tesamorelin works through one endocrine lever, GHRH-receptor agonism raising pulsatile growth hormone and IGF-1, and the domains downstream of that lever carry named clinical endpoints of varying quality. Visceral fat and hepatic fat are validated lanes with randomized support from Falutz 2007, Stanley 2014 and Stanley 2019. Thinner edges include metabolic markers in responders per Stanley 2012, fat quality per Lake 2021, trunk muscle area per Adrian 2019, and cognition, where Baker 2012 showed an executive-function effect but Ellis 2025 found no neurocognitive separation from standard care in HIV. That mix is the SM-066 band for several validated lanes with thinner edges.
Evidence quality (Exceptional): Tesamorelin reaches the top SM-050 band by route A, replicated human trials. The package includes two Phase 3 randomized trials with imaging endpoints, safety extension data through fifty-two weeks, a separate randomized HIV-NAFLD trial, and Badran 2026's five-RCT meta-analysis, plus FDA approval and a DHHS guideline naming tesamorelin as the only approved therapy for excess abdominal fat in people with HIV. Tesamorelin sits at that band's floor rather than its ceiling for two documented reasons: the Cochrane review covering the area is withdrawn, and the evidence is confined to the HIV phenotype while most reader interest in tesamorelin is off-label extrapolation.
Speed of onset (Moderate): Tesamorelin is slow where tesamorelin matters. IGF-1 rises within days, but the SM-067 speed ladder discounts an onset whose first mover is a lab value rather than something the person feels, and the endpoints that justify tesamorelin run long: visceral fat is assessed at thirteen to twenty-six weeks, Stanley 2019 used a twelve-month liver-fat frame, and Baker 2012 ran twenty weeks. The packet's own first-noticeable estimate is four weeks, with subjective sleep deepening reported earlier. That places tesamorelin in the band for a biomarker shifting over weeks with no meaningful acute effect.
Durability (Limited): Tesamorelin benefit does not survive discontinuation. The DHHS and NIH HIV guidelines state plainly that visceral-fat reductions reverse after stopping tesamorelin, and Falutz 2010's extension data support regression. The SM-066 durability ladder instructs the scorer to read the discontinuation sentence rather than the treatment-period sentence, and tesamorelin's discontinuation sentence is explicit. Tesamorelin amplifies an endocrine signal while present and does not permanently reset adipose biology, liver-fat tendency or GH-axis aging, so realistic planning looks like chronic therapy. That is the band where benefit requires continued use and disappears within months of stopping.
Bioindividuality (Strong): Tesamorelin is phenotype-dependent in the way the SM-067 ladder rewards rather than punishes, because the predictor is knowable before a reader starts. High baseline visceral fat, HIV-associated lipodystrophy, imaging-confirmed HIV-associated fatty liver, or low-normal IGF-1 identify likely responders in advance, and Stanley 2012's pooled responder analysis showed those responders also carried better triglyceride and glucose patterns. Lake 2021 adds that response includes adipose-quality change, not only depot size. Within that selected population a clear majority respond with variance partly explained, which is the band tesamorelin occupies; low-visceral-fat adults with normal IGF-1 simply have little headroom.
What are the risks & downsides of Tesamorelin?
Downside contribution: 2.06 (safety risks weighted extra)
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | Moderate | 0.750 | |
| Side effects | 15% | Moderate | 0.375 | |
| Cost premium | 5% | High | 0.200 | |
| Effort | 5% | Moderate | 0.125 | |
| Opportunity | 5% | Moderate | 0.130 | |
| Dependency | 15% | High | 0.525 | |
| Reversibility | 25% | Low | 0.450 | |
| Total | 2.555 | |||
| Harm subtotal × 1.4 | 2.940 | |||
| Opportunity subtotal × 1.0 | 0.455 | |||
| Combined downside | 3.395 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.055 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Cost premium: premium over the cheapest legitimate route, not price.
Downside Rationale
Tesamorelin still needs caution because the downside profile depends on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight, not only on the headline benefit. Financial cost is the dominant downside, while safety and effort sit lower and shift by user type. Badran et al. 2026 supports the core benefit, but the same evidence base leaves gaps around long-term use, nonresponders, and people outside the studied population. The downside is not only adverse events; it is also cost, effort, sourcing quality, contraindications, and the chance of chasing the wrong lever. That makes screening and expectation-setting part of the intervention.
Safety (Moderate): Tesamorelin carries one quantified metabolic harm and a set of screened contraindications, placing it at the top of the population-specific band rather than the organ-toxicity band. Phase 3 trials showed new-onset diabetes at about five percent versus one percent on placebo, an odds ratio of 3.3, which weighs heaviest in prediabetes and is monitorable through HbA1c and fasting glucose. The FDA 2025 label contraindicates active malignancy, pregnancy and hypothalamic-pituitary disruption and warns on fluid retention and elevated IGF-1. The neoplasm warning is the generic growth-axis concern SM-060 excludes as a class-wide theoretical risk, and a completed human safety programme exists, so SM-074 does not apply.
Side effects (Moderate): Tesamorelin produces a named, common tolerability cluster: arthralgia, myalgia, paresthesia, peripheral edema and injection-site reactions, reported across the trial base and confirmed in Badran 2026's meta-analysis. The decisive datum is that Falutz 2007 recorded more adverse-event withdrawals on tesamorelin than on placebo, which is the SM-067 band's own test for effects frequent and disruptive enough to drive early discontinuation. SM-022 keeps the glucose-intolerance signal in Safety and out of this dimension, so tesamorelin is not double-charged. Starting below label dose smooths tolerability for tesamorelin without removing the monitoring requirement.
Cost premium (High): Tesamorelin is one of the most financially restrictive outpatient interventions in the catalog. The cheapest legitimate route, which is what SM-026 and SM-007a require scoring, is compounded tesamorelin through telehealth at roughly two hundred fifty to five hundred dollars a month at two milligrams daily; branded Egrifta SV reaches several thousand dollars monthly without coverage, and coverage depends on documented HIV-associated lipodystrophy plus prior authorization. A proprietary product priced many multiples above a cheaper equivalent route is the SM-067 band tesamorelin occupies, and the spec's own worked example places tesamorelin at that anchor.
Effort (Moderate): Tesamorelin demands daily subcutaneous injection plus reconstitution of a lyophilized vial, site rotation, cold-chain handling, sharps disposal, evening timing to align with nocturnal growth-hormone physiology, and periodic IGF-1, fasting glucose and HbA1c monitoring. The injection itself takes a couple of minutes, which alone would sit in the few-minutes-a-day band where tirzepatide's weekly shot scores low, but tesamorelin's daily cadence plus genuine preparation and laboratory follow-up meets the SM-067 description of meaningful preparation. Tesamorelin is therefore harder than an oral supplement and easier than infusion therapy, and the friction compounds over months.
Opportunity cost (Moderate): Tesamorelin sits just above the band where a concrete better-evidenced alternative exists in the same category. For a reader whose goal is visceral fat or metabolic risk generally, GLP-1 therapy, training, sleep apnea treatment and liver imaging are better-evidenced uses of the same budget, and tesamorelin's concentrated cost makes that displacement real rather than notional. Stacking tesamorelin with CJC-1295 is redundant because both act at the GHRH receptor. Tesamorelin stays out of the crowded-category band because within its labelled indication the DHHS/NIH guideline names tesamorelin the only approved therapy, so for that population no better-evidenced substitute exists at all.
Dependency (High): Tesamorelin creates no craving, intoxication, tolerance or withdrawal syndrome, and the packet reports no evidence of permanent pituitary damage at label dosing. What tesamorelin does create is the exact pattern the SM-066 ladder reserves for its upper non-addictive band: the primary outcome tesamorelin exists to produce reverses on stopping. The DHHS and NIH guidelines state that visceral-fat reduction regresses after discontinuation, so maintaining the result requires continuing the drug, which is structurally the tirzepatide case the ladder anchors at that value. Repeated cycles without maintenance habits become a costly loop for tesamorelin users.
Reversibility (Low): Tesamorelin clears cleanly while its separate durability problem is routed elsewhere, which is precisely the SM-067 band that anchors tirzepatide at 1.7. Systemic half-life is about twenty-six minutes, the growth-hormone pulse and IGF-1 elevation return toward baseline after stopping, and no implant, structural change or permanent biochemical alteration is involved. Discontinuation is far cleaner than surgery or an implanted device. The loss of visceral-fat and liver-fat benefit on stopping is scored once in Durability under SM-046 and is deliberately not counted again here, and the underlying neoplasm and glucose risks are scored once in Safety and likewise excluded.
Is Tesamorelin worth it?
Tesamorelin is a 6.0–6.5/10 fit for body composition, hormonal, metabolic health, especially for readers who can match the protocol to HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. The best evidence anchors are Badran et al. 2026, which Meta-analysis of 5 RCTs; found reductions in VAT, trunk fat, limb fat, hepatic fat percentage, and waist circumference, with increased lean body mass, and Russo et al. 2024, which INSTI-regimen subgroup analysis; reductions in visceral fat, hepatic fat fraction, and trunk-to-appendicular fat ratio; below Track 1 size threshold. Tesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for hepatic fat reduction, but cost, daily injections, reversibility, cancer contraindications, and anti-doping prohibition keep the score at 6.0–6.5/10.
✅ Best for: Adults with HIV-associated abdominal lipodystrophy who fit the FDA-labeled indication and can access prescription Egrifta SV with clinician monitoring. Tesamorelin is also worth discussing for HIV-associated NAFLD or early MASH under hepatology or infectious-disease supervision, especially when liver fat is imaging-confirmed. Select older adults or MCI patients with low-normal IGF-1 may reasonably track the cognitive research, but cognition should remain secondary. Best-case users monitor IGF-1, HbA1c, fasting glucose, edema, arthralgia, retinopathy risk, and cancer history while using tesamorelin as part of a broader body composition and metabolic health plan.
❌ Avoid if: Avoid tesamorelin with active malignancy, prior malignancy without oncology clearance, pregnancy, trying to conceive, hypothalamic-pituitary disruption, severe or active diabetic retinopathy, poorly controlled diabetes, acute critical illness, or prior hypersensitivity to tesamorelin or mannitol. Competitive athletes should avoid tesamorelin because WADA prohibits growth hormone-releasing factors at all times. Also avoid tesamorelin if the goal is casual weight loss, rapid aesthetics, unmonitored longevity experimentation, or cheap gray-market peptide use. If you cannot commit to daily injections, lab monitoring, and months-long tracking, a lower-friction sleep or metabolic intervention is a better first move.
Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.
What is Tesamorelin best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Body Composition / Fat Loss: 7.5/10
Score: 7.5/10Tesamorelin scores 7.5/10 for body composition, with the best signal coming from Badran et al. 2026. Phase 3 HIV lipodystrophy evidence supports the strongest body-composition signal: Falutz 2007 showed VAT reduction with subcutaneous fat largely preserved, and Stanley 2012 linked responder VAT loss to improved metabolic markers. The score stays bounded because Tesamorelin evidence for body composition can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Hormonal / Endocrine: 7.5/10
Score: 7.5/10For hormonal, Tesamorelin lands at 7.5/10 because Russo et al. 2024 supports the core mechanism. Tesamorelin directly stimulates the GHRH receptor and raises IGF-1 through a feedback-intact pituitary pathway. Falutz 2007 supports the GH/IGF-1 axis effect in the pivotal HIV lipodystrophy population. The score stays bounded because Tesamorelin evidence for hormonal can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Metabolic Health: 7.0/10
Score: 7.0/10The metabolic health use case earns 7.0/10 for Tesamorelin, anchored by Ellis et al. 2025. Tesamorelin reduces VAT and triglyceride-related risk markers, but glucose effects are mixed. Stanley 2012 found VAT responders had better lipid and glucose patterns than nonresponders, while FDA labeling still warns about glucose intolerance. The score stays bounded because Tesamorelin evidence for metabolic health can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Liver / Detoxification: 6.5/10
Score: 6.5/10Evidence puts Tesamorelin at 6.5/10 for liver detox, mainly through Falutz et al. 2007. HIV-associated fatty liver data support a meaningful liver-fat signal. Stanley 2019 tested tesamorelin in HIV-associated NAFLD, and Fourman 2020 reported hepatic transcriptomic changes consistent with less inflammatory and fibrotic signaling. The score stays bounded because Tesamorelin evidence for liver detox can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cognition / Focus: 6.5/10
Score: 6.5/10Cognition Focus is a 6.5/10 fit for Tesamorelin, based on the evidence summarized in Falutz et al. 2008. The cognition signal comes mainly from Baker 2012, which reported improved cognitive function in older adults after GHRH analog treatment. A 2025 HIV neurocognition trial was smaller and did not show a clear neurocognitive advantage. The score stays bounded because Tesamorelin evidence for cognition focus can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cardiovascular: 6.0/10
Score: 6.0/10The practical cardiovascular read is 6.0/10 for Tesamorelin, with Falutz et al. 2010 setting the ceiling. Tesamorelin improves some cardiometabolic risk surrogates through VAT reduction, triglyceride changes, inflammatory-marker shifts, and possibly carotid or adipose-quality pathways. Stanley 2011 supports inflammatory-marker improvement tied to VAT response. The score stays bounded because Tesamorelin evidence for cardiovascular can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Geriatric / Aging Population: 6.0/10
Score: 6.0/10Tesamorelin reaches 6.0/10 for geriatric when the goal matches the population in Stanley et al. 2011. Tesamorelin targets an age-sensitive GH/IGF-1 axis and may improve VAT, cognition, and muscle quality in select older adults, but the geriatric case is conditional. Adrian 2019 supports exploratory muscle-quality changes in HIV responders. The score stays bounded because Tesamorelin evidence for geriatric can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Memory: 5.5/10
Score: 5.5/10A 5.5/10 memory rating fits Tesamorelin, since Stanley et al. 2012 points to a real but bounded effect. Baker 2012 reported memory-related improvement after GHRH analog therapy in older adults and MCI. The score stays moderate because replication and disease-specific neurodegeneration outcomes remain limited. The score stays bounded because Tesamorelin evidence for memory can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Neuroprotection: 5.5/10
Score: 5.5/10For readers tracking neuroprotection, Tesamorelin deserves 5.5/10 because Stanley et al. 2014 gives the strongest anchor. GH/IGF-1 signaling supports neuronal survival and synaptic function, and Baker 2012 gives human cognitive signal. Direct neuroprotection outcomes, dementia delay, and structural brain endpoints remain unproven for tesamorelin. The score stays bounded because Tesamorelin evidence for neuroprotection can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Healthspan: 5.5/10
Score: 5.5/10The evidence-weighted call is 5.5/10 for Tesamorelin in healthspan, led by Stanley et al. 2019. Tesamorelin improves VAT, liver fat, and selected metabolic markers in high-risk groups, which may support healthspan. The score stays capped because GH/IGF-1 signaling has complex aging biology and no lifespan or hard healthspan outcome trials. The score stays bounded because Tesamorelin evidence for healthspan can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Anti-Inflammatory: 5.0/10
Score: 5.0/10Tesamorelin has a 5.0/10 anti inflammatory case because Fourman et al. 2020 supports a plausible benefit. Stanley 2011 reported inflammatory-marker changes that tracked with visceral-fat reduction, and Fourman 2020 showed downregulation of hepatic inflammatory gene sets in HIV-associated NAFLD. The score stays bounded because Tesamorelin evidence for anti inflammatory can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
| Use Case | Score | Summary |
|---|---|---|
| ○ Sleep Quality | 4.5 | Nick's personal review reports deeper sleep, and bedtime dosing matches nocturnal GH physiology. Controlled tesamorelin polysomnography evidence is absent, so this stays an experiential and mechanistic subrating rather than a clinical sleep claim. |
| ○ Muscle Growth / Hypertrophy | 4.5 | GH/IGF-1 signaling can support lean tissue, and Adrian 2019 found increased trunk muscle area and density in HIV tesamorelin responders. Strength transfer and direct hypertrophy outcomes remain modest. |
| ○ Recovery / Repair | 4.5 | Tesamorelin raises an anabolic repair axis through GH and IGF-1, but recovery-specific tesamorelin trials are lacking. The score reflects indirect endocrine support, not proven recovery acceleration in athletes or injury populations. |
| ○ Strength / Power | 4.0 | Tesamorelin may improve lean tissue quality in responders, as in Adrian 2019, but lean mass or muscle-density changes do not automatically translate into maximal strength or power output. |
| ○ Neuroplasticity | 4.0 | IGF-1 supports synaptic plasticity and brain repair pathways, and Baker 2012 gives a human cognition signal. Direct tesamorelin neuroplasticity biomarkers remain sparse. |
| ○ Energy / Fatigue | 4.0 | Improved VAT, sleep quality, and metabolic markers may improve subjective energy in selected users. Tesamorelin has no stimulant mechanism, and energy outcomes were not primary endpoints in the pivotal evidence. |
| ○ Sleep Architecture (Deep/REM) | 4.0 | Bedtime dosing tries to amplify the natural slow-wave-sleep GH pulse. The timing logic is coherent, but controlled sleep-architecture endpoints with tesamorelin have not established a robust clinical effect. |
| ○ Longevity / Lifespan | 4.0 | Longevity scoring remains cautious because GH/IGF-1 biology cuts both ways: metabolic improvements may help high-VAT adults, while higher IGF-1 can raise theoretical cancer-growth concern in susceptible users. |
| ○ Injury Recovery | 3.5 | GH/IGF-1 supports connective tissue and soft-tissue repair generally, but there are no tesamorelin-specific injury-recovery trials. The score reflects endocrine plausibility and indirect evidence only. |
| ○ Circadian Rhythm / Chronobiology | 3.5 | Evening tesamorelin dosing aligns with nocturnal GH secretion, but tesamorelin is not a circadian-reset intervention. Any circadian benefit is secondary to sleep timing and endocrine pulse matching. |
| ○ Blood Sugar / Glycemic Control | 3.5 | Tesamorelin can modestly worsen glucose tolerance in susceptible users despite VAT benefits. FDA labeling warns about glucose intolerance and diabetes monitoring, so blood-sugar scoring remains intentionally conservative. |
| ○ Bone / Joint Health | 3.5 | GH/IGF-1 signaling supports bone remodeling, but tesamorelin trials did not establish DEXA bone-density improvement or joint-specific benefit. Arthralgia is also a known tolerability issue. |
| ○ Wound Healing | 3.0 | GH can support tissue repair, but tesamorelin-specific wound-healing trials are absent. This rating remains low-moderate because the intervention is not clinically established for wounds. |
| ○ Skin / Beauty | 3.0 | GH/IGF-1 can influence dermal thickness and collagen turnover, but tesamorelin has no strong skin-aging RCT evidence. Any skin benefit is indirect and should not drive use. |
| ○ Mood / Emotional Regulation | 3.0 | Body-image and quality-of-life improvements appear in HIV lipodystrophy evidence, but tesamorelin is not a mood treatment. Mood benefit is most likely secondary to body composition, sleep, or metabolic improvements. |
| ○ Libido / Sexual Health | 3.0 | GH restoration may indirectly support sexual function in deficient or metabolically impaired adults, but tesamorelin has no direct libido trial evidence. The score stays exploratory. |
| ○ Traumatic Brain Injury | 3.0 | Post-TBI pituitary dysfunction can involve GH deficiency, but tesamorelin itself has not been tested as a TBI therapy. Endocrine evaluation matters more than unsupervised peptide use. |
| ○ Mitochondrial | 3.0 | Fourman 2020 reported hepatic oxidative-phosphorylation gene changes in HIV-associated NAFLD, but tesamorelin is not a direct mitochondrial therapy. The mitochondrial score remains indirect. |
Compare Tesamorelin with
Frequently Asked Questions
How does tesamorelin differ from taking growth hormone directly?
Tesamorelin stimulates your pituitary's own GH pulse instead of replacing growth hormone directly. Falutz 2007 showed IGF-1 elevation and VAT reduction through this GHRH analog pathway. Exogenous HGH bypasses pituitary feedback and can create more continuous exposure. That does not make tesamorelin risk-free: active malignancy, pregnancy, hypothalamic-pituitary disruption, glucose intolerance, and elevated IGF-1 monitoring still matter.
What is the actual dose for biohacker use vs the FDA label?
The FDA-labeled dose is 2 mg subcutaneous daily for HIV-associated lipodystrophy. Off-label biohacker protocols often use 1 mg at night, sometimes 5 days on and 2 days off, but that lower-dose cycling is not the pivotal-trial protocol. Higher 3 to 4 mg/day community dosing exceeds the evidence base and likely increases edema, arthralgia, paresthesia, injection reactions, and glucose risk without proven added benefit.
What does the visceral fat evidence actually show?
Tesamorelin has the strongest evidence for reducing visceral adipose tissue in HIV-associated lipodystrophy. Falutz 2007 is the landmark Phase 3 trial, and Falutz 2010 supports the extension pattern. Subcutaneous fat is generally preserved, which distinguishes tesamorelin from simple calorie restriction. The drawback: benefits fade after discontinuation, so long-term use or a maintenance bridge is usually needed.
Does tesamorelin help liver fat and NAFLD?
Tesamorelin has promising HIV-associated NAFLD evidence, but it is not a general-population MASH drug. Stanley 2019 tested tesamorelin for HIV-associated NAFLD over 12 months, and Fourman 2020 found hepatic transcriptomic changes tied to oxidative phosphorylation, inflammation, and fibrosis pathways. General MASH histology outcomes still need larger confirmation outside the HIV subgroup.
What does the cognition and brain data look like?
The cognition signal is real but not settled. Baker 2012 reported cognitive improvement in older adults after GHRH analog treatment, including people with MCI. Ellis 2025 was a smaller HIV neurocognition trial and did not show a clear neurocognitive advantage over standard care. Treat cognition as an investigational use, especially if baseline IGF-1 is already normal.
Is tesamorelin safer than exogenous HGH long-term?
Tesamorelin is probably cleaner than exogenous HGH mechanistically, but long-term safety is not unlimited. The FDA label lists active malignancy and pregnancy as contraindications and warns about neoplasms, elevated IGF-1, glucose intolerance, fluid retention, hypersensitivity, injection-site reactions, and acute critical illness. Long-term cardiovascular safety has not been established, so monitoring matters.
How does compounded tesamorelin compare to brand Egrifta for cost and quality?
Brand Egrifta SV is the evidence-aligned supply route, but cost is the major barrier. Non-approved compounded or research-peptide tesamorelin can be much cheaper, yet identity, sterility, and endotoxin testing are not equivalent to an FDA-approved product. That risk belongs to sourcing, not the molecule itself. For prescription use, start with the approved route and insurance documentation before considering anything else.
How should tesamorelin be timed and stacked with other peptides?
Evening injection is the usual timing because endogenous GH secretion peaks during slow-wave sleep. Stacking tesamorelin with CJC-1295 is usually redundant because both stimulate the GHRH receptor. A tesamorelin plus ipamorelin-style stack is more coherent mechanistically because it combines GHRH and ghrelin/GHRP signaling, but no RCT validates stacked peptide dosing. Keep stacking experimental and monitor IGF-1 and glucose.
What could change Tesamorelin's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Phase 3 MASH trial positive on histologic endpoints | Efficacy 4.0 to 4.5; Evidence 4.5 to 5.0; Breadth 4.0 to 4.5 | 6.3 / 10 👍 Worth trying |
| Phase 3 cognitive or MCI trial confirms the GHRH cognition signal | Efficacy 4.0 to 4.5; Evidence 4.5 to 5.0 | 6.2 / 10 👍 Worth trying |
| Long-term cancer incidence signal appears in post-market surveillance | Safety 2.5 to 4.0 | 5.2 / 10 ⚖️ Neutral |
| Generic tesamorelin approval brings cost under $500/month | Cost 4.5 to 2.5 | 6.1 / 10 👍 Worth trying |
| FDA allows 503A compounding during supply disruption with verified quality controls | Cost 4.5 to 3.0 | 6.0 / 10 👍 Worth trying |
| Independent replication plus cardiovascular outcomes data confirms lower event risk | Evidence 4.5 to 5.0; Breadth 4.0 to 4.5 | 6.2 / 10 👍 Worth trying |
Key Evidence Sources
- Badran et al. 2026 - Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials, Obesity Research & Clinical Practice. Meta-analysis of 5 RCTs; found reductions in VAT, trunk fat, limb fat, hepatic fat percentage, and waist circumference, with increased lean body mass.
- Russo et al. 2024 - Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, AIDS. INSTI-regimen subgroup analysis; reductions in visceral fat, hepatic fat fraction, and trunk-to-appendicular fat ratio; below Track 1 size threshold.
- Ellis et al. 2025 - Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity, Journal of Infectious Diseases. Open-label randomized phase 2 trial; waist circumference improved, but neurocognitive benefit did not significantly differ from standard care.
- Falutz et al. 2007 - Metabolic effects of a growth hormone-releasing factor in patients with HIV, New England Journal of Medicine. Landmark Phase 3 trial; reduced VAT, improved lipid/body-image measures, increased IGF-1, and had more adverse-event withdrawals than placebo.
- Falutz et al. 2008 - Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation, AIDS. Longer-term HIV abdominal-fat accumulation data supporting sustained treatment effect and safety monitoring.
- Falutz et al. 2010 - Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: randomized placebo-controlled trial with safety extension, JAIDS. Randomized placebo-controlled trial plus safety extension; supports VAT reduction and regression after discontinuation.
- Stanley et al. 2011 - Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat, AIDS. 410 HIV-infected patients; inflammatory and fibrinolytic marker changes related to VAT reduction.
- Stanley et al. 2012 - Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin, Clinical Infectious Diseases. Pooled responder analysis; VAT responders had better triglyceride and glucose-marker patterns than nonresponders.
- Stanley et al. 2014 - Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial, JAMA. 50-person RCT; tesamorelin reduced visceral fat and liver fat over 6 months in HIV abdominal-fat accumulation.
- Stanley et al. 2019 - Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: randomized, double-blind, multicentre trial, Lancet HIV. 61-person HIV-associated NAFLD trial; reduced liver fat and informed later hepatic transcriptomic analyses.
- Fourman et al. 2020 - Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD, JCI Insight. Mechanistic follow-up using paired liver biopsy specimens; showed changes in oxidative phosphorylation, inflammatory, tissue-repair, and fibrosis-related gene pathways.
- Lake et al. 2021 - Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity, Journal of Clinical Endocrinology & Metabolism. Secondary analysis showing improved VAT and SAT density independent of fat-quantity changes among responders.
- Adrian et al. 2019 - The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV, Journal of Frailty & Aging. Exploratory secondary analysis; tesamorelin responders had improved trunk muscle area and density versus placebo.
- Baker et al. 2012 - Growth hormone-releasing hormone improves cognitive function in adults with mild cognitive impairment and healthy older adults, Archives of Neurology. 20-week cognition RCT of GHRH analog therapy in older adults and MCI; supports but does not settle cognitive use.
- FDA 2025 - EGRIFTA WR prescribing label. Current FDA labeling: indication, limitations, contraindications, warnings, and dosing.
- DHHS/NIH 2025 - Weight Gain in People With HIV, Adult and Adolescent ART Guidelines. Guideline mentions tesamorelin as the only US FDA-approved therapy for excessive abdominal fat in people with HIV and notes reversal after discontinuation.
- Cochrane 2013 withdrawn review page - Treatment of lipodystrophy in patients with HIV infection. Cochrane page exists but the review is withdrawn; no active Cochrane tesamorelin position located in the audit.
- WADA 2026 - Prohibited List, growth hormone-releasing factors. Tesamorelin is listed under growth hormone-releasing factors and prohibited at all times in sport.
What does the evidence say about Tesamorelin?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
On the Outliyr Podcast, Jay Campbell noted: “Tesamorelin is almost impossible to get because it is a controlled FDA regulated and approved peptide known as Egrifta.” (EP113).
Citations: Falutz 2007, Falutz 2010, Stanley 2011, Stanley 2012, Stanley 2019, Fourman 2020, Russo 2024, Ellis 2025, Badran 2026, FDA 2025
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Egrifta FDA approval 2010, Egrifta SV reformulation 2018, DHHS HIV Guidelines 2025
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Tesamorelin
The lenses mostly diverge rather than converge. Modern evidence supports tesamorelin for a narrow, clinically defined metabolic phenotype, with meaningful off-label signals for HIV-associated NAFLD and weaker cognition data. Historical evidence explains why the drug exists: HIV lipodystrophy created a specific unmet need that diet and exercise often did not solve. Traditional evidence is effectively absent. Honest synthesis: tesamorelin belongs in monitored medical or advanced biohacker contexts where VAT, liver fat, IGF-1, glucose, and contraindications are measured, not in casual wellness stacks.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- IGF 1 Baseline (pre-protocol) During | Expected Up
- Fasting Glucose During | Expected Watch
- HbA1c Post | Expected Watch
- ALT During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Sleep During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Abdominal Fullness Scale 1-5 | During | Expected Down
- Water Retention Scale 1-5 | During | Expected Watch
- Joint Stiffness Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe edema or carpal tunnel symptoms
- Fasting glucose drift upward
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.835 − 2.055 = 0.780
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.780 / 4.00) × 5 = 6.0 / 10
